TABLE 3.
Q1 | Q2 | Q3 | Q4 | P-trend2 | |
---|---|---|---|---|---|
Total invasive breast cancer | |||||
Cases, n | 424 | 416 | 437 | 423 | |
Age-adjusted | 1.00 (reference) | 0.99 (0.86, 1.13) | 0.94 (0.82, 1.08) | 0.91 (0.79, 1.04) | 0.17 |
MV-adjusted3 | 1.00 (reference) | 0.98 (0.86, 1.13) | 0.94 (0.82, 1.07) | 0.90 (0.78, 1.03) | 0.15 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 0.98 (0.86, 1.12) | 0.87 (0.76, 1.00) | 0.91 (0.79, 1.05) | 0.28 |
ER+ breast cancer | |||||
Cases, n | 311 | 313 | 326 | 319 | |
Age-adjusted | 1.00 (reference) | 1.00 (0.86, 1.17) | 0.95 (0.81, 1.11) | 0.92 (0.79, 1.08) | 0.35 |
MV-adjusted3 | 1.00 (reference) | 0.99 (0.84, 1.16) | 0.93 (0.80, 1.09) | 0.90 (0.76, 1.06) | 0.23 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 0.98 (0.84, 1.15) | 0.90 (0.77, 1.06) | 0.93 (0.79, 1.09) | 0.58 |
ER– breast cancer | |||||
Cases, n | 59 | 50 | 60 | 48 | |
Age-adjusted | 1.00 (reference) | 0.86 (0.59, 1.25) | 0.94 (0.66, 1.35) | 0.75 (0.51, 1.10) | 0.18 |
MV-adjusted3 | 1.00 (reference) | 0.88 (0.60, 1.29) | 0.96 (0.67, 1.39) | 0.77 (0.52, 1.14) | 0.25 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 0.93 (0.65, 1.32) | 0.72 (0.49, 1.06) | 0.69 (0.47, 1.03) | 0.06 |
ER+/PR+ breast cancer | |||||
Cases, n | 276 | 264 | 260 | 261 | |
Age-adjusted | 1.00 (reference) | 0.96 (0.81, 1.14) | 0.86 (0.73, 1.02) | 0.86 (0.73, 1.02) | 0.11 |
MV-adjusted3 | 1.00 (reference) | 0.94 (0.80, 1.12) | 0.85 (0.71, 1.01) | 0.85 (0.71, 1.01) | 0.09 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 0.91 (0.77, 1.08) | 0.86 (0.73, 1.03) | 0.89 (0.74, 1.06) | 0.31 |
ER–/PR– breast cancer | |||||
Cases, n | 54 | 48 | 56 | 41 | |
Age-adjusted | 1.00 (reference) | 0.90 (0.61, 1.33) | 0.96 (0.66, 1.40) | 0.70 (0.46, 1.05) | 0.16 |
MV-adjusted3 | 1.00 (reference) | 0.93 (0.63, 1.37) | 0.99 (0.68, 1.45) | 0.72 (0.47, 1.10) | 0.24 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 0.97 (0.67, 1.40) | 0.75 (0.51, 1.12) | 0.64 (0.42, 0.98) | 0.04 |
ER–/PR–/HER2– breast cancer | |||||
Cases, n | 38 | 38 | 37 | 27 | |
Age-adjusted | 1.00 (reference) | 1.02 (0.65, 1.60) | 0.91 (0.58, 1.44) | 0.66 (0.40, 1.09) | 0.06 |
MV-adjusted3 | 1.00 (reference) | 1.04 (0.66, 1.64) | 0.93 (0.58, 1.47) | 0.68 (0.41, 1.13) | 0.08 |
MV-adjusted excluding alcohol3, 4 | 1.00 (reference) | 1.21 (0.79, 1.85) | 0.73 (0.45, 1.19) | 0.65 (0.38, 1.09) | 0.02 |
Values are HRs (95% CIs) unless otherwise indicated. ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; MET, metabolic equivalent of task; MV, multivariable; PR, progesterone receptor.
P value for the continuous AHEI-2010 score (Wald test).
Adjusted for total energy intake (kcal/d, continuous), race/ethnicity (white [reference], black, other), income (<$50,000 [reference], $50,000 to <$100,000, ≥$100,000/y), smoking (0, >0 to <10, 10 to <20, 20 to <30, ≥30 pack-years), BMI (<18.5, 18.5 to <25 [reference], 25 to <30, 30 to <35, ≥35), physical activity (MET-h/wk, continuous), height (inches, continuous), education (high school or less [reference], some college, college graduate or more), mother diagnosed with breast cancer (yes vs. no [reference]), age at first live birth (nulliparous [reference], <21, 21 to <25, 25 to <29, 29–32, >32 y), parity (0 or 1 [reference], 2 or 3, 4 or more), hormone replacement therapy (none [reference], estrogen only, estrogen and progesterone, both estrogen and progesterone), age at menopause (premenopausal [reference], <40, 40 to <50, 50 to <55, ≥55 y), oral contraception use (yes [reference] vs. no), age at menarche (<12 [reference], 12 to <12.5, 12.5 to <13.5, 13.5 to <14.5, ≥14.5 y), lifetime duration of breastfeeding (0 [reference], >0 to <50, 50 to <100, ≥100 wk), and time of last mammogram (<1 [reference], 1 to <2, ≥2 y ago).
Additionally adjusted for alcohol intake (none [reference], <0.5, ≥0.5 to 1, ≥1 to 2, ≥2 drinks/d).